- The first and only treatment in Europe to treat patients with molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare,...
Promising efficacy and safety profiles were observed in prior Phase II studies in acute ischemic stroke patients treated with recanalization...
NEW YORK, NY and Tel Aviv, ISRAEL, Sept. 16, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Todos Medical, Ltd. (OTCQB:...
New York, NY, and Tel Aviv, ISRAEL, Sept. 15, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB:...
– Scientific collaborators at Stanford University will present data on an imaging and treatment regimen demonstrating the microglial targeting of...
NEEDHAM, Mass., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL) (Candel or the Company), a late clinical...
TORONTO, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device...
Signals of Clinical Benefit Detected in Small Phase 2 Study, Suggesting Potential to Show Statistically Significant Therapeutic Benefit in Larger,...
LA JOLLA, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market...
Follows CDC & World Health Organization's (WHO) announcement that US now meets criteria for country with circulating vaccine-derived poliovirus (cVDPV)Surveillance wastewater and...
AGOURA HILLS, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), developer of treatments...
Cigna® Issues Favorable Policy for Deep TMS to Address Medication-Resistant Obsessive-Compulsive DisorderBURLINGTON, Mass. and JERUSALEM, Israel, Sept. 14, 2022 (GLOBE...
WOBURN, Mass., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Axial Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to the development of...
LAVAL, Québec, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST),...
Las Vegas, NV, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a...
ABILITY Study will evaluate MDNA11, a highly selective long-acting IL-2 Superkine, in combination with Merck’s KEYTRUDA® (pembrolizumab) for treatment of...
-The IND for AK-OTOF is the first to receive FDA clearance for a genetic form of hearing loss and the...
LAVAL, Québec, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST),...
SOUTH SAN FRANCISCO, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated...
Broad antitumor immune responses and demonstration of durable disease control from solid tumor patients who previously failed one or more...